PROLOR Biotech Inc

PROLOR Biotech — Merger or Acquisition (April 2013)

13 slides from PROLOR Biotech's merger presentation, Apr 24, 2013

  1. Slide 1: Merger Overview April 2013

    Merger Overview April 25 2013 NYSE: OPK NYSE Mkt : PBTH

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains " forward - looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes,"

  3. Slide 3: Additional Information and Where to Find It

    Additional Information and Where to Find It This presentation is being made pursuant to and in compliance with Rules 165 and 425 of the Securities Act of 1933 and does not constitute an offer of any securities for sale or a solicitation of an offer to buy any securities. In connection with the propo

  4. Slide 4: Participants in the Merger Solicitation

    Participants in the Merger Solicitation PROLOR, OPKO and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from PROLOR and OPKO shareholders in connection with the proposed transaction. Information about PROLOR’s directors and executive

  5. Slide 5: OPKO Corporate Overview

    OPKO Corporate Overview ( 1 ) A U.S. public company listed on NYSE (NYSE: OPK) A multi - national biopharmaceutical and diagnostics company, 549 employees Developing a range of solutions to diagnose, treat and prevent various conditions, including point - of - care tests, laboratory developed tests

  6. Slide 6: OPKO Corporate Overview: Israeli Holdings

    OPKO Corporate Overview ( 2 ) OPKO holds interest in two Israeli private companies: Fine Tech Pharmaceuticals, Ltd. (Acquired in December 2011 ) Develops and produces high value, high potency, difficult to make active pharmaceutical ingredients FDA registered state of the art facility in Nesher , Is

  7. Slide 7: OPKO: Main Products Overview

    OPKO: Main Products Overview Commercial – Spain, Chile, Mexico & Brazil Sales of generic & branded generic ($ 47 mn in 2012 ) Therapeutic drugs : Next generation potent vitamin D insufficiency therapy (Phase III, U.S. market $ 1.5 bn ) Next generation phosphate binder for treatment of hyperphosphate

  8. Slide 8: PROLOR's Pipeline of Market Leaders

    Indication Product Market Size Preclin. Ph I Ph II Ph III Growth Hormone Disorders hGH – CTP (Adults) $3B hGH – CTP (Children) Hemophilia Factor VIIa - CTP $1.3B 1 - 2/ week injection Factor IX - CTP $0.7B 1/week injection Diabetes Type II & Obesity Oxyntomodulin $2B 1/week injection PROLOR’s Pipeli

  9. Slide 9: Merger Terms

    Merger Terms OPKO to acquire all of the outstanding equity of PROLOR 0.9951 shares of OPKO stock for each share of PROLOR stock $ 7 per share of PROLOR, ~$ 480 million ( 63.75 million shares and 8.1 million options + warrants) based on a 10 - day VWAP of OPKO’s stock All - stock deal Largest - ever

  10. Slide 10: Merger Rationale (PROLOR)

    Merger Rationale (PROLOR) Leverage OPKO’s existing and planned commercial sales infrastructure Vitamin D products sold through nephrologists and endocrinologists Use same sales infrastructure for hGH - CTP upon approval OPKO’s management team vastly experienced and with a superior track record in li

  11. Slide 11: Merger Rationale (PROLOR)

    Merger Rationale (PROLOR) Preserve and enhance PROLOR’s Israeli R&D center Allow our talented and dedicated development team to continue the development of the various programs and platforms without any interruption Expand the Israeli R&D operations into what will hopefully become Israel’s most prom

  12. Slide 12: PROLOR Post Merger

    PROLOR Post Merger PROLOR Biotech Ltd. to remain an independent subsidiary of OPKO No planned change in management, employees, location. PROLOR to be defined as the biotechnology R&D global center of OPKO Same R&D and clinical development responsibilities hGH - CTP, Factor VIIa , Obesity & Diabetes

  13. Slide 13: Thank You

    Thank You PROLOR BIOTECH Protein Longevity. Redefined

PROLOR Biotech — Merger or Acquisition (April 2013) on 6ix